BRCA mutations

For the first time, an investigator initiated phase 1b study tested the combination of the PARP inhibitor olaparib, and the AKT inhibitor capivasertib, and showed this combination was well tolerated and achieved durable responses in patients with treatment-refractory breast, ovarian…

Over 450 departments and institutions worldwide have contributed to the most comprehensive study conducted so far on breast cancer risk variants whose results have been published in Nature Genetics. The fine mapping of 150 breast cancer risk regions identified nearly…